The IND is part of a pattern of progress on multiple fronts. Arcadia has raised $9.25M from investors including Sam Altman, Fred Ehrsam, and Dylan Field. The company has also secured a patent for ...
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage – NV-387 Could Become a Revolutionary Antiviral for ...
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, ...
Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated ...
Plus: Proposed regulations for “no tax on tips,” new tax forms, Roth catch-up contributions, charitable donation deductions, ...
A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ('Bluejay” or the 'Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously ...
Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combi ...
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...
The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback